NZ602579A - Mitochondrially delivered anti-cancer compounds - Google Patents
Mitochondrially delivered anti-cancer compoundsInfo
- Publication number
- NZ602579A NZ602579A NZ602579A NZ60257909A NZ602579A NZ 602579 A NZ602579 A NZ 602579A NZ 602579 A NZ602579 A NZ 602579A NZ 60257909 A NZ60257909 A NZ 60257909A NZ 602579 A NZ602579 A NZ 602579A
- Authority
- NZ
- New Zealand
- Prior art keywords
- cancerous cell
- pro
- domain
- moiety
- oxidant
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
- C07F9/6552—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring
- C07F9/65522—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring condensed with carbocyclic rings or carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
- A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
- C07D311/70—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with two hydrocarbon radicals attached in position 2 and elements other than carbon and hydrogen in position 6
- C07D311/72—3,4-Dihydro derivatives having in position 2 at least one methyl radical and in position 6 one oxygen atom, e.g. tocopherols
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2008901261A AU2008901261A0 (en) | 2008-03-14 | Mitochondrially Delivered Anti-Cancer Compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ602579A true NZ602579A (en) | 2013-12-20 |
Family
ID=41064682
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ602579A NZ602579A (en) | 2008-03-14 | 2009-03-16 | Mitochondrially delivered anti-cancer compounds |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | USRE47300E1 (https=) |
| EP (1) | EP2265623B1 (https=) |
| JP (1) | JP5616798B2 (https=) |
| KR (1) | KR101642157B1 (https=) |
| CA (1) | CA2734208C (https=) |
| NZ (1) | NZ602579A (https=) |
| WO (1) | WO2009111846A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103764026B (zh) | 2011-04-14 | 2016-10-19 | 艾伦斯生物科技有限公司 | 用于肝细胞癌的诊断、预后、监测和治疗的方法 |
| WO2012174287A1 (en) * | 2011-06-15 | 2012-12-20 | The Board Of Regents Of The University Of Texas System | Luminescent nanoparticle compositions |
| HK1200459A1 (en) | 2011-09-19 | 2015-08-07 | Gencia Corporation | Modified creatine compounds |
| WO2013181488A2 (en) * | 2012-06-01 | 2013-12-05 | The Ohio State University Research Foundation | Inhibition of leukemic stem cells by pp2a activating agents |
| PT2989110T (pt) * | 2013-04-24 | 2018-11-15 | Jira Neuzil | Derivados de tamoxifeno para o tratamento de doenças neoplásicas, especialmente com nível elevado de proteína her2 |
| US10953110B2 (en) | 2014-04-25 | 2021-03-23 | Board Of Regents, The University Of Texas System | Dual emissive metal nanoparticles as ratiometric pH indicators |
| WO2016144637A1 (en) * | 2015-03-06 | 2016-09-15 | The Children's Hospital Of Philadelphia | Tocopheryloxyacetate ester-based co-drug conjugates |
| CZ307146B6 (cs) * | 2015-03-31 | 2018-02-07 | Kkcg Se | Trifenylfosfoniové analogy biguanidu, způsob jejich přípravy a jejich použití jako léčiva |
| US20180318324A1 (en) | 2015-11-04 | 2018-11-08 | Prescient Pharma Llc | Anti-aging compositions and methods for using same |
| KR102361131B1 (ko) * | 2020-02-25 | 2022-02-10 | 경희대학교 산학협력단 | 항생제 내성 균주에 대해 항균활성을 갖는 항균용 조성물 |
| TW202233246A (zh) * | 2020-10-22 | 2022-09-01 | 南韓商白雁生物技術公司 | 含有抗癌劑之粒線體及其用途 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030069208A1 (en) * | 1997-11-25 | 2003-04-10 | University Of Otago | Mitochondrially targeted antioxidants |
| US6331532B1 (en) * | 1998-11-25 | 2001-12-18 | University Of Otago | Mitochondrially targeted antioxidants |
| KR100847678B1 (ko) | 2000-02-11 | 2008-07-23 | 리서치 디벨럽먼트 파운데이션 | 토코페롤, 토코트리에놀, 다른 크로만 및 측쇄 유도체, 및이들의 용도 |
| AUPQ605800A0 (en) * | 2000-03-06 | 2000-03-30 | Silverbrook Research Pty Ltd | Printehead assembly |
| WO2002093063A1 (en) * | 2001-05-17 | 2002-11-21 | Imperial College Innovations Limited | Production and processing plant with a rigid pipe portion curving in three dimensions |
| BRPI0413742B8 (pt) | 2003-08-22 | 2021-05-25 | Antipodean Pharmaceuticals Inc | composto antioxidante quimicamente estável, composição farmacêutica, método de redução do estresse oxidativo em uma célula in vitro e métodos de preparo e de síntese do referido composto antioxidante |
| CN1925853B (zh) * | 2004-07-28 | 2011-01-26 | 陈献 | 琥珀酸α-生育酚酯及其类似物和盐的稳定注射组合物 |
| KR100556527B1 (ko) * | 2004-11-04 | 2006-03-06 | 삼성전자주식회사 | 트렌치 소자 분리막 형성 방법 및 불휘발성 메모리 장치의제조 방법 |
| WO2006094203A1 (en) | 2005-03-02 | 2006-09-08 | Northeastern University | Mitochondriotropic phospholipid vesicles |
| RU2318500C2 (ru) | 2005-10-18 | 2008-03-10 | Общество С Ограниченной Ответственностью "Митотехнология" | Способ воздействия на организм путем адресной доставки биологически активных веществ в митохондрии, фармацевтическая композиция для его осуществления и соединение, применяемое для этой цели |
| NZ575920A (en) | 2006-09-15 | 2012-08-31 | Stephen John Ralph | Pro-oxidant anti-cancer compounds |
| JP4930026B2 (ja) * | 2006-12-13 | 2012-05-09 | 富士ゼロックス株式会社 | 積層体、無端状ベルト、定着装置及び画像形成装置 |
| DE102007025423A1 (de) | 2007-05-30 | 2008-12-04 | Friedrich-Schiller-Universität Jena | Triphenylphosphonium-Derivate zum gezielten Transport und Freisetzen von Substanzen in Mitochondrien sowie Verfahren zu deren Verwendung |
-
2009
- 2009-03-16 NZ NZ602579A patent/NZ602579A/en not_active IP Right Cessation
- 2009-03-16 US US14/955,297 patent/USRE47300E1/en not_active Expired - Fee Related
- 2009-03-16 JP JP2010550000A patent/JP5616798B2/ja active Active
- 2009-03-16 WO PCT/AU2009/000312 patent/WO2009111846A1/en not_active Ceased
- 2009-03-16 EP EP09720005.9A patent/EP2265623B1/en not_active Not-in-force
- 2009-03-16 KR KR1020107022874A patent/KR101642157B1/ko active Active
- 2009-03-16 US US12/922,525 patent/US8598145B2/en not_active Ceased
- 2009-03-16 CA CA2734208A patent/CA2734208C/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP5616798B2 (ja) | 2014-10-29 |
| EP2265623A4 (en) | 2014-01-01 |
| AU2009225261A1 (en) | 2009-09-17 |
| JP2011513437A (ja) | 2011-04-28 |
| CA2734208A1 (en) | 2009-09-17 |
| US20110105437A1 (en) | 2011-05-05 |
| US8598145B2 (en) | 2013-12-03 |
| EP2265623B1 (en) | 2016-07-13 |
| WO2009111846A4 (en) | 2009-11-05 |
| CA2734208C (en) | 2018-01-09 |
| USRE47300E1 (en) | 2019-03-19 |
| EP2265623A1 (en) | 2010-12-29 |
| WO2009111846A1 (en) | 2009-09-17 |
| KR101642157B1 (ko) | 2016-07-22 |
| KR20100135803A (ko) | 2010-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ602579A (en) | Mitochondrially delivered anti-cancer compounds | |
| BR112013002631A2 (pt) | preparações cosméticas | |
| UY31215A1 (es) | Compuestos de morfolino pirimidina, procesos para su preparacion, composiciones farmacéuticas conteniéndolos y su uso en terapia. | |
| GB2433070A (en) | Porphyrin derivatives and their use in photon activation therapy | |
| MX345238B (es) | (aralquilamino y heteroarilalquilamino alfa-substituidos)pirimidin ilo y 1,3,5-triazinilbenzimidazoles, composiciones farmacéuticas que los contienen, y estos compuestos para su uso en el tratamiento de enfermedades proliferativas. | |
| EP1430061A4 (en) | INCLUSION COMPOUND CONTAINING CUCURBITURIL DERIVATIVES AS RECEPTOR MOLECULE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | |
| AR088622A1 (es) | 18-METIL-6,7-METILEN-3-OXO-17-PREGN-4-EN-21,17b-CARBOLACTONA, PREPARADOS FARMACEUTICOS QUE CONTIENEN LOS COMPUESTOS MENCIONADOS Y SU USO EN LA TERAPIA DE LA ENDOMETRIOSIS | |
| WO2005044181A3 (en) | Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors | |
| ECSP11011113A (es) | Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades | |
| WO2008070336A3 (en) | Hypoxia-selective, weakly basic 2-nitroimidazole delivery agents and methods of use thereof | |
| JO2848B1 (en) | Organic compounds | |
| WO2010111406A3 (en) | Purine derivatives useful as anti - cancer agents | |
| NO20080442L (no) | Fosforamidat alkylator promedikament | |
| BR112013031039A2 (pt) | hidrazino 1h-imidazoquinolina-4-aminas e conjugados feitos disso | |
| BR112014002670A2 (pt) | uso de monoésteres de isossorbida como compostos antimicrobianamente ativos | |
| UY32644A (es) | Compuesto anticancerígeno y composición farmacéutica que lo contiene | |
| MX2010013682A (es) | Derivados de 2,4-diamino-l,3,5-triazina triciclicos utiles para el tratamiento del cancer y trastornos mieloproliferativos. | |
| CR11362A (es) | Bisfosfonatos de alquilo de 2 a 5 atomos de carbono-imidazol | |
| BR112014002594A2 (pt) | uso de diésteres de isossorbida como espessantes | |
| UA107455C2 (uk) | Похідні індолу як протиракові агенти | |
| MX2017012102A (es) | Agentes citotoxicos bifuncionales que contienen el farmacoforo de cti. | |
| CR20150007A (es) | Derivados de estra-1,3,5(10),16-tetraeno 3-sustituidos, metodos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos | |
| WO2005065074A3 (en) | Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors | |
| WO2010151074A3 (ko) | 양자점-클로린 유도체의 접합체를 함유하는 광감작제 및 이를 포함하는 광역학 치료에 사용하기 위한 암 치료 및 진단용 조성물 | |
| MY162934A (en) | Anticancer steroidal lactones unsaturated in position 7 (8) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 16 MAR 2016 BY CULLENS Effective date: 20150121 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 MAR 2017 BY CULLENS PTY LTD Effective date: 20160316 |
|
| ASS | Change of ownership |
Owner name: CANCURE LIMITED, AU Effective date: 20160728 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 MAR 2018 BY CULLENS PTY LTD Effective date: 20170223 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 MAR 2019 BY CULLENS PTY LTD Effective date: 20180227 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 MAR 2020 BY DR. STEFFEN SCHWARZ IPRIS AG Effective date: 20190312 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 MAR 2021 BY DR. STEFFEN SCHWARZ Effective date: 20200310 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 MAR 2022 BY BIRGIT KNAACK Effective date: 20210304 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 MAR 2023 BY BIRGIT KNAACK Effective date: 20220304 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 MAR 2024 BY PAVIS PAYMENTS GMBH Effective date: 20230302 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 MAR 2025 BY BIRGIT KNAACK Effective date: 20240229 |
|
| LAPS | Patent lapsed |